155 related articles for article (PubMed ID: 26982101)
61. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases.
Wittig BM
Curr Opin Investig Drugs; 2007 Nov; 8(11):947-54. PubMed ID: 17979029
[TBL] [Abstract][Full Text] [Related]
62. Immunoglobulin interface redesigning to enhance lebrikizumab mediated immunomodulation of IL-13 hyper-response.
Sharma V; Chouhan P; Pandey RK; Ojha R; Aathmanathan VS; Krishnan M; Prajapati VK
J Biomol Struct Dyn; 2021 Jul; 39(11):4051-4065. PubMed ID: 32448082
[TBL] [Abstract][Full Text] [Related]
63. Role of the C-terminus in the activity, conformation, and stability of interleukin-6.
Ward LD; Hammacher A; Zhang JG; Weinstock J; Yasukawa K; Morton CJ; Norton RS; Simpson RJ
Protein Sci; 1993 Sep; 2(9):1472-81. PubMed ID: 8401231
[TBL] [Abstract][Full Text] [Related]
64. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
65. The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling.
Feng J; Li Y; Shen B
Peptides; 2004 Jul; 25(7):1123-31. PubMed ID: 15245871
[TBL] [Abstract][Full Text] [Related]
66. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.
Harms BD; Kearns JD; Su SV; Kohli N; Nielsen UB; Schoeberl B
Methods Enzymol; 2012; 502():67-87. PubMed ID: 22208982
[TBL] [Abstract][Full Text] [Related]
67. Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure-Activity Relationships and Molecular Docking.
Nada H; Sivaraman A; Lu Q; Min K; Kim S; Goo JI; Choi Y; Lee K
J Med Chem; 2023 Apr; 66(7):4417-4433. PubMed ID: 36971365
[TBL] [Abstract][Full Text] [Related]
68. [EMABling
de Romeuf C
Med Sci (Paris); 2019 Dec; 35(12):1160-1162. PubMed ID: 31903931
[No Abstract] [Full Text] [Related]
69. Reversal of Autoimmune Toxicity and Loss of Tumor Response by Interleukin-17 Blockade.
Esfahani K; Miller WH
N Engl J Med; 2017 May; 376(20):1989-91. PubMed ID: 28514612
[No Abstract] [Full Text] [Related]
70. Current methods for the generation of human antibodies for the treatment of autoimmune diseases.
Osbourn J; Jermutus L; Duncan A
Drug Discov Today; 2003 Sep; 8(18):845-51. PubMed ID: 12963321
[TBL] [Abstract][Full Text] [Related]
71. [IL-6 as a target in autoimmune disease and inflammation].
Hashizume M; Ohsugi Y
Nihon Yakurigaku Zasshi; 2014 Oct; 144(4):172-7. PubMed ID: 25312286
[No Abstract] [Full Text] [Related]
72. Therapeutic antibodies for autoimmunity and inflammation.
Chan AC; Carter PJ
Nat Rev Immunol; 2010 May; 10(5):301-16. PubMed ID: 20414204
[TBL] [Abstract][Full Text] [Related]
73. Molecular interaction analysis of anti-IL-8 scFv-10F8-6His against IL-8 monomer through molecular docking and molecular dynamic simulations.
Abdul Kadir FFN; Che Nordin MA; S M N Mydin RB; Choong YS; Che Omar MT
J Biomol Struct Dyn; 2023 Oct; ():1-11. PubMed ID: 37837430
[TBL] [Abstract][Full Text] [Related]
74. Development of therapeutic antibodies for the treatment of diseases.
Lu RM; Hwang YC; Liu IJ; Lee CC; Tsai HZ; Li HJ; Wu HC
J Biomed Sci; 2020 Jan; 27(1):1. PubMed ID: 31894001
[TBL] [Abstract][Full Text] [Related]
75. Computational approaches to therapeutic antibody design: established methods and emerging trends.
Norman RA; Ambrosetti F; Bonvin AMJJ; Colwell LJ; Kelm S; Kumar S; Krawczyk K
Brief Bioinform; 2020 Sep; 21(5):1549-1567. PubMed ID: 31626279
[TBL] [Abstract][Full Text] [Related]
76. In Silico Maturation of a Nanomolar Antibody against the Human CXCR2.
Buratto D; Wan Y; Shi X; Yang G; Zonta F
Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139124
[TBL] [Abstract][Full Text] [Related]
77. Protein-protein interaction and in silico mutagenesis studies on IL17A and its peptide inhibitor.
Kochhar A; Khan NS; Deval R; Pradhan D; Jena L; Bhuyan R; Sahu TK; Jain AK
3 Biotech; 2021 Jun; 11(6):305. PubMed ID: 34194898
[TBL] [Abstract][Full Text] [Related]
78. Letter from the editor.
Reichert JM
MAbs; 2009; 1(5):393. PubMed ID: 20065631
[No Abstract] [Full Text] [Related]
79. Natural products as IL-6 inhibitors for inflammatory diseases: Synthetic and SAR perspective.
Harmalkar DS; Sivaraman A; Nada H; Lee J; Kang H; Choi Y; Lee K
Med Res Rev; 2024 Jul; 44(4):1683-1726. PubMed ID: 38305581
[TBL] [Abstract][Full Text] [Related]
80. No added sugar: antibody makers find an upside to 'no fucose'.
Garber K
Nat Biotechnol; 2018 Nov; 36(11):1025-1027. PubMed ID: 30412203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
